RT Journal Article
SR Electronic
T1 Rituximab as a first-line preventive treatment in pediatric NMOSDs
JF Neurology - Neuroimmunology Neuroinflammation
JO Neurol Neuroimmunol Neuroinflamm
FD Lippincott Williams & Wilkins
SP e46
DO 10.1212/NXI.0000000000000046
VO 1
IS 4
A1 Giulia Longoni
A1 Brenda Banwell
A1 Massimo Filippi
A1 E. Ann Yeh
YR 2014
UL http://nn.neurology.org/content/1/4/e46.abstract
AB Objective: No established therapeutic protocol has been proposed to date for childhood-onset neuromyelitis optica (NMO) spectrum disorders (NMOSDs). We report the response of 5 NMO immunoglobulin (Ig)G–positive pediatric cases to a standardized B-cell–targeted first-line immunosuppressive protocol with rituximab for prevention of relapses.Methods: Retrospective observational cohort study.Results: All patients included in the study showed disease remission after rituximab induction. Relapses always occurred in conjunction with CD19+ B-cell repopulation and appeared less severe than prior to treatment. At the end of follow-up, neurologic disability and MRI findings stabilized or improved in all the patients, with only minor and transient side effects. Oral steroid discontinuation was possible in all the patients.Conclusions: Our protocol is well-tolerated and has provided encouraging results in terms of control of relapses and progression of disability. An early intervention with rituximab might affect the disease course in pediatric NMO-IgG–positive NMOSDs.Classification of evidence: This study provides Class IV evidence that for children with NMOSDs, rituximab is well-tolerated and stabilizes or improves neurologic disability.AQP4=aquaporin-4; EDSS=Expanded Disability Status Scale; Ig=immunoglobulin; NMO=neuromyelitis optica; NMOSD=neuromyelitis optica spectrum disorder